{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"41","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"97.5","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"ORR4 for CTCL cohorts is defined as the percentage of participants that have achieved a CR or PR lasting at least 4 months per global response criteria and the modified severity weighted assessment tool (mSWAT). ORR4 and 95% exact confidence interval is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 80 mg QD CTCL"}],"paramType":"NUMBER","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"Up to 36.4 weeks","title":"Part 2: Objective Response Rate Lasting at Least 4 Months (ORR4) (CTCL Cohorts)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}